All In Biotech

Drug Trial Radar · NCT05337345

A Study to Evaluate the Drug Levels of Cendakimab Delivered Subcutaneously in Healthy Participants

A Phase I, Open-Label, Randomized, Two-part Parallel Study to Compare the Pharmacokinetics of Single Subcutaneous Injections of Cendakimab Administered Using Autoinjector Versus Using Prefilled Syringe, and to Evaluate the Pharmacokinetics of Cendakimab When Administered by Autoinjector at Different Injection Sites, in Healthy Participants

Last checked: Nov 19, 2026Latest source record: Feb 10, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 104 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

104

Actual

Start

May 2, 2022

Primary completion

Dec 15, 2022

Study completion Dec 15, 2022

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Apr 20, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the drug levels of cendakimab delivered subcutaneously in healthy participants.

Conditions

  • Healthy Volunteers

Interventions

  • CendakimabDrug

    Specified Dose on Specified Days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum observed concentration (Cmax)Time frame: Up to Day 105
  2. Area under the concentration-time curve (AUC) from time zero to time of last quantifiable concentration (AUC(0-T))Time frame: Up to Day 105
  3. AUC from time zero extrapolated to infinite time (AUC(INF))Time frame: Up to Day 105

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Anaheim Clinical Trials Llc

    Anaheim, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.